| Literature DB >> 33072079 |
Fengxia Ding1,2,3,4, Bo Liu2,5, Chao Niu1,2,3,4, Ting Wang1,2,3,4, Yaping Wang1,2,3,4, Gang Geng1,2,3,4, Daiyin Tian1,2,3,4, Jihong Dai1,2,3,4, Zhou Fu1,2,3,4.
Abstract
The mechanism(s) underlying endotoxin tolerance in asthma remain elusive. As the endotoxin lipopolysaccharide (LPS) affects the expression of the regulatory T-cell (Treg)-suppressive glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) on antigen-presenting dendritic cells (DCs), we hypothesized that LPS-induced changes in DC GITRL expression may impact Treg-mediated T-helper (Th) cell suppression and the induction of endotoxin tolerance. Here, we propose a novel mechanism by which low-dose LPS inhalation in neonatal mice induces endotoxin tolerance, thereby offering protection from later asthma development. Three-day old wild-type and Toll-like receptor 4 (TLR4)-deficient neonatal mice were exposed to low-dose LPS (1 μg) intranasally for 10 consecutive days prior to ovalbumin (OVA)-induced asthma to better understand the tolerogenic mechanism(s) of low-dose LPS pre-exposure. In vivo findings were validated using in vitro co-culturing studies of primary CD11c+ DCs and CD4+ T-cells with or without low-dose LPS pre-exposure before OVA stimulation. Low-dose LPS pre-exposure upregulated the Treg response and downregulated pathogenic Th2 and Th17 responses through promoting apoptosis of Th2 and Th17 cells. Low-dose LPS pre-exposure downregulated DC GITRL expression and T-cell GITR expression. Artificial DC GITRL expression abrogated the tolerogenic Treg-skewing effect of low-dose LPS pre-exposure. Low-dose LPS pre-exposure inhibited TRIF/IRF3/IFNβ signaling and upregulated expression of tolerogenic TRIF/IRF3/IFNβ negative regulators in a TLR4-dependent manner. This tolerogenic DC GITRL downregulation was attributable to TRIF/IRF3/IFNβ signaling inhibition. Low-dose LPS pre-exposure produces tolerogenic Treg skewing in neonatal asthmatic mice, a phenomenon attributable to TLR4-dependent TRIF/IRF3/IFNβ-mediated DC GITRL downregulation.Entities:
Keywords: GITRL; LPS; TLR4; asthma; endotoxin tolerance
Mesh:
Substances:
Year: 2020 PMID: 33072079 PMCID: PMC7538595 DOI: 10.3389/fimmu.2020.02150
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
FIGURE 1Experimental protocol for constructing murine model of asthma. Neonatal BALB/c mice received daily low-dose LPS (1 μg) or PBS (control) intranasally (i.n.) from the 3rd DOL for a period of 10 consecutive days. Mice were then sensitized with 100 μg OVA plus 100 μl aluminum hydroxide (AlOH) or PBS (control) via intraperitoneal (i.p.) injection on the 42nd DOL and 56th DOL, and then further exposed to a daily, 30-min 1% OVA aerosol or PBS aerosol (control) from the 63rd DOL for a period of 10 consecutive days. Twenty-four hours after the last OVA challenge, the mice were sacrificed. n = 6–8 mice per group.
FIGURE 2Lung-derived dendritic cell GITRL expression downregulated in low-dose LPS-pre-exposed asthmatic mice relative to untreated asthmatic mice. (A,B) Immunohistochemistry of GITRL in lung tissue sections. Left panel (200× magnification) scale bars = 50 μm, right panel (400× magnification) scale bars = 100 μm. (C,D) Immunofluorescence of GITRL in lung tissue sections. Scale bars (200× magnification) = 50 μm. (E,F) Membrane-fraction immunoblotting of GITRL expression in lung-derived CD11c+CD11b+ dendritic cells. (G) Flow cytometry of surface GITRL expression on lung-derived CD11c+CD11b+ dendritic cells. n = 6–8 mice per group. Data are reported as means ± standard deviations (SDs). *p < 0.05 and ***p < 0.001 vs. Control group; ##p < 0.01 and ###p < 0.001 vs. PBS/OVA group. Control, unexposed normal mice; PBS/OVA, asthmatic mice; 3d1μgLPS/OVA, low-dose (1 μg daily) LPS-exposed asthmatic mice with LPS exposure at 3rd DOL; 3d1μgLPS/PBS, low-dose (1 μg daily) LPS-exposed normal mice with LPS exposure at 3rd DOL.
FIGURE 3Co-culture of low-dose LPS-pre-exposed dendritic cells and T-cells prior to OVA stimulation downregulates dendritic cell GITRL expression. GITRL expression on CD11c+CD11b+ dendritic cells were significantly downregulated in the low-dose LPS-exposed LPS/OVA cells (100 ng/ml LPS) as compared with PBS/OVA cells. (A) Surface GITRL expression on primary dendritic cells by immunofluorescence. Scale bars (600× magnification) = 150 μm. (B) Membrane-fraction immunoblotting of GITRL expression on primary dendritic cells. (C) Surface GITRL expression on primary dendritic cells by flow cytometry. Data are reported as means ± standard deviations (SDs). **p < 0.01 vs. Control group; #p < 0.05 and ##p < 0.01 vs. PBS/OVA group. Control, unexposed normal mice; PBS/OVA, asthmatic mice; LPS/OVA, low-dose LPS-exposed asthmatic mice; LPS/PBS, low-dose LPS-exposed normal mice.
FIGURE 4Pulmonary effects of GITRL silencing or overexpression on low-dose LPS-pre-exposed asthmatic mice. (A) Representative images of lung tissue sections stained with hematoxylin and eosin (H&E) 24 h after the final challenge. Left panel (200× magnification) scale bars = 50 μm, right panel (400× magnification) scale bars = 100 μm. (B) Lung resistance (LR) values in reaction to increasing doses of methacholine were measured 24 h after the final challenge. (C) Inflammation score in each group. (D) Serum OVA-specific IgE levels as measured by ELISA. n = 6–8 mice per group. Data are reported as means ± standard deviations (SDs). *p < 0.05, **p < 0.01, and ***p < 0.001 vs. PBS/OVA group; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. 3d1μgLPS/OVA group. Control, unexposed normal mice; Control + Vector, unexposed normal mice with empty vector; PBS/OVA, asthmatic mice; 3d1μgLPS/OVA, low-dose LPS-exposed asthmatic mice; 3d1μgLPS/OVA + GITRL-siRNA, low dose LPS-exposed asthmatic mice with GITRL-siRNA DCs; 3d1μgLPS/OVA + GITRL-OE, low dose LPS-exposed asthmatic mice with GITRL-overexpressing DCs.
FIGURE 5Low-dose LPS pre-exposure downregulates TLR4-dependent TRIF/IRF3/IFNβ pathway activation in dendritic cells. TLR4-mediated TRIF/IRF3/IFNβ pathway activation in CD11c+CD11b+ dendritic cells was significantly downregulated in the low-dose LPS-exposed LPS/OVA cells (100 ng/ml LPS) as compared with PBS/OVA cells. (A) Whole-cell lysate immunoblotting of TLR4 and TBK1 following immunoprecipitation with anti-TRIF antibodies in primary dendritic cells. (B) Whole-cell lysate immunoblotting of TLR4/TRIF/TBK1/IRF3 pathway proteins in primary dendritic cells. (C) Whole-cell lysate immunoblotting of IFNβ (left panels) and supernatant levels of IFNβ as measured by ELISA (right panel) in primary dendritic cells. (D) Whole-cell lysate immunoblotting of four key negative regulators of the TLR4/TRIF/TBK1/IRF3 pathway proteins in primary dendritic cells. Data are reported as means ± standard deviations (SDs). **p < 0.01 and ***p < 0.001 vs. Control group; ###p < 0.001 vs. PBS/OVA group; ††p < 0.01 and †††p < 0.001 vs. WT.
FIGURE 6IFNβ exposure rescues dendritic cell GITRL downregulation from low-dose LPS pre-exposure. (A) Surface GITRL expression on primary CD11c+CD11b+ dendritic cells by flow cytometry. (B) Membrane-fraction immunoblotting of GITRL expression on primary CD11c+CD11b+ dendritic cells. (C) Flow cytometry of surface GITRL expression on lung-derived CD11c+CD11b+ dendritic cells. (D) Membrane-fraction immunoblotting of GITRL expression in lung-derived CD11c+CD11b+ dendritic cells. Data are reported as means ± standard deviations (SDs). **p < 0.01 and ***p < 0.001 vs. Control group; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. PBS/OVA group. Control, unexposed normal mice; PBS/OVA, asthmatic mice; 3d1μgLPS/OVA, low-dose (1 μg daily) LPS-exposed asthmatic mice with LPS exposure at 3rd DOL; 3d1μgLPS/PBS, low-dose (1 μg daily) LPS-exposed normal mice with LPS exposure at 3rd DOL.